Skip to main content
Lupin Ltd logo

Lupin Ltd — Investor Relations & Filings

Ticker · LUPIN ISIN · INE326A01037 LEI · 335800HHXTESDEE2FC65 BSE.NS Manufacturing
Open in API
Filings indexed 3,180 across all filing types
Latest filing 2023-01-09 Regulatory Filings
Country IN India
Listing BSE.NS LUPIN

About Lupin Ltd

https://www.lupin.com/

Lupin Ltd is a global pharmaceutical organization specializing in the development, manufacturing, and marketing of a comprehensive range of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients. The company holds a significant market position in therapeutic segments such as cardiovascular, diabetology, asthma, pediatrics, gastrointestinal, anti-infectives, and non-steroidal anti-inflammatory drugs. It is notably recognized for its leadership in the anti-tuberculosis medication sector. With a strong emphasis on research and development, Lupin focuses on complex generics, specialty medicines, and biosimilars. The company operates advanced manufacturing facilities and maintains a substantial commercial presence across major global markets, including North America, Europe, and the Asia-Pacific region, delivering affordable and high-quality healthcare solutions.

Recent filings

Filing Released Lang Actions
Certificate under Reg. 74(5) of SEBI (DP) Regulations, 2018 for the quarted ended at December 31, 2022.
Regulatory Filings
2023-01-09 English
Lupin and Exeltis Announce Reimbursement Approval of NaMuscla® in Spain for the Symptomatic Treatment of Myotonia in Adults with non-dystrophic myotonic (NDM) Disorders.
Regulatory Filings Classification · 95% confidence The document is a press release dated January 9, 2023, announcing the approval of reimbursement by the Spanish Ministry of Health for Lupin's drug NaMuscla for treatment of myotonia. It is addressed to stock exchanges and regulatory bodies under SEBI Listing Regulations, indicating it is a regulatory disclosure. The content focuses on a business update regarding product reimbursement approval and market access, not financial results or detailed financial statements. There is no indication of financial data, earnings, management discussion, or audit information. The document is a corporate announcement about a regulatory and commercial milestone, typical of a Regulatory Filing (RNS) category. It is not a report, transcript, or detailed financial document, but a formal disclosure under listing obligations.
2023-01-09 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing the approval of reimbursement by the Spanish Ministry of Health for Lupin's NaMuscla® for treatment of myotonia in adults with non-dystrophic myotonic disorders. It is addressed to stock exchanges as a disclosure pursuant to SEBI regulations. The content focuses on the announcement of a regulatory and commercial milestone rather than financial results, management changes, or detailed financial data. It does not contain financial statements, earnings data, or detailed management discussion. The document is a corporate announcement about a product reimbursement approval and related business update. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and disclosure under listing obligations, rather than any specific financial report or other category.
2023-01-09 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short announcement dated January 8, 2023, informing stock exchanges about the company's participation in the J.P. Morgan Healthcare Conference on January 10, 2023. It references Regulation 30(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, which pertains to disclosure of events or information. The document states that presentations will be filed electronically later, indicating this is a notification rather than the presentation or report itself. The length is only 1704 characters, which is quite short and consistent with an announcement rather than a full report or transcript. Therefore, this document is best classified as an Investor Presentation announcement or notification. However, since the actual presentation is not included but only the notice of participation and forthcoming presentation, the most appropriate classification is Regulatory Filings (RNS) as a general regulatory announcement about an upcoming investor presentation event, not the presentation itself.
2023-01-08 English
J. P. Morgan Healthcare Conference on Tuesday, January 10, 2023.
Investor Presentation Classification · 90% confidence The document is a short notice dated January 8, 2023, informing stock exchanges about the company's participation in the J.P. Morgan Healthcare Conference on January 10, 2023. It references Regulation 30(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of material events. The document states that presentations will be filed electronically with the exchanges but does not contain the presentations themselves or any financial data. The length is only 1699 characters, indicating it is a brief announcement rather than a full report or transcript. Therefore, this document is best classified as an Investor Presentation announcement or notification of participation in an investor event. Given the options, the closest and most appropriate classification is Investor Presentation (IP).
2023-01-08 English
Lupin Receives Approval from U.S. FDA for Fesoterodine Fumarate Extended-Release Tablets.
Regulatory Filings Classification · 95% confidence The document is a press release announcing the receipt of U.S. FDA approval for a pharmaceutical product (Fesoterodine Fumarate Extended-Release Tablets). It is addressed to stock exchanges under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of material events. The document does not contain financial statements, detailed financial analysis, or management discussion. It is a regulatory disclosure about a significant corporate event (FDA approval) rather than a financial report or earnings release. The document length is 4130 characters, which is relatively short and consistent with a regulatory announcement. Therefore, the most appropriate classification is Regulatory Filings (RNS), as it is a general regulatory announcement that does not fit into other specific categories like earnings release or annual report.
2023-01-06 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.